Skip to content
Events

 

Euan Ashley, MD, PhD
Associate Dean, School of Medicine, Professor of Medicine (Cardiovascular), of Genetics, of Biomedical Data Science and by courtesy, of Pathology
Stanford University Medical Center

Cardiovascular Genomics: From Leonardo to Precision Health

 

Details

Fill Out Form to Access Webinar

Your email address is never shared with third parties.

Date & Time
27 Oct. 2020
Topic
Complex disease genomics, Genetic & rare diseases
Watch Now

Related Events

Nov 6
Your Vision Our Workflow - Illumina’s solution for clinical research in rare and inherited disease
Nov 6, 2024
In this webinar you will hear from two speakers: Anthony Beckhouse on the benefits and flexibility of the NextSeq 1K/2k, and Michael Fietz on the accuracy and speed of our secondary analysis solution DRAGEN, as well as how our tertiary analysis solution Emedgene can help address bottlenecks of analysis and reporting for rare and inherited disease research. With Illumina’s exome or genome sequencing as a backbone, and the ability to do virtual panels with our tertiary solution - Emedgene. Laboratories can now create comprehensive assays to enable the latest genomic discoveries.
View Event
Nov 6
Your Vision Our Workflow - Illumina’s solution for clinical research in rare and inherited disease
Nov 6, 2024
In this webinar you will hear from two speakers: Anthony Beckhouse on the benefits and flexibility of the NextSeq 1K/2k, and Michael Fietz on the accuracy and speed of our secondary analysis solution DRAGEN, as well as how our tertiary analysis solution Emedgene can help address bottlenecks of analysis and reporting for rare and inherited disease research. With Illumina’s exome or genome sequencing as a backbone, and the ability to do virtual panels with our tertiary solution - Emedgene. Laboratories can now create comprehensive assays to enable the latest genomic discoveries.
View Event
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.